As per the International Osteoporosis Foundation, osteoporosis is a
disease in which the density and quality of bones reduce. Losing bone density
is a normal part of aging process, however, in some cases it leads to the
development of osteoporosis. As bones becomes more
porous and fragile, the risk of fracture increases. Most common fractures
associated with osteoporosis occurs at hip, wrist and vertebrae.
High prevalence of osteoporosis, growing ageing population, and
increasing life expectancy are anticipated to aid the demand for osteoporosis
drugs in the United States over the next five years. Moreover, an increasing
number of international players foraying the market coupled with growing
awareness regarding osteoporotic care among consumers is expected to have a
positive impact on the osteoporosis drugs market in the United States in the
“United States Osteoporosis Drugs Market
Opportunities, 2011 - 2021” report
studies the market size and share of various segments and sub-segments of the osteoporosis
drugs market in the United States
during the period 2011 - 2021. In the study, the market has been categorized
into six broader segments that include Bisphosphonates,
Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid
Hormone (PTH), Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
The market dynamics section of the report
elaborates the factors that are driving the market as well as the challenges
inhibiting growth. The research study also includes insights of the key market
trends, a detailed analysis of the changing competitive landscape, and revenue
forecasts for each segment and sub-segment.
this information is provided to assist the established market players and new
entrants in taking their strategic decisions, thereby aiding them in
strengthening their market position in a highly competitive osteoporosis
drugs market in the United States.
Drugs Market Opportunities, 2011 - 2021”
report elaborates the following aspects of osteoporosis
drugs market in the United States:
ü United States Osteoporosis
Size, Share & Forecast
ü Segmental Analysis – By Type (Bisphosphonates, Calcitonins,
Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH),
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) & Others), By Sales
Channel (Retail & Non Retail), By Region, By Company
ü Policy & Regulatory Landscape
ü Changing Market Trends & Emerging Opportunities
ü Competitive Landscape & Strategic
Why You Should Buy This Report?
ü To identify the on-going trends and anticipated
growth in the next five years
ü To gain competitive knowledge of leading market
ü To avail 10% customization in the report without
any extra charges and get the research data or trends added in the report as
per the buyer’s specific needs
Questions This Study Will Answer
ü What would be the segmental
and regional growth trends in the United
States osteoporosis drugs market
in the coming years?
ü What are the most important
growth drivers and opportunities in the market?
ü Which drug is preferred the most?
ü What strategies should market
competitors employ to gain share in mature segments of the United States osteoporosis drugs market?
ü What are the competitor
profiles in this market and how do they compete for market share?
information contained in this report is based upon both primary and secondary
sources. Primary research included interviews with osteoporosis drugs industry
experts. Secondary research included an exhaustive search of relevant
publications like company annual reports, financial reports and other